{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000027","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.384474+00:00","generated_at":"2026-06-02T06:09:45.243124+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"vTv Therapeutics Q1 net loss $4.9M; cash rises to $52.3M on $51M placement, Phase 3 on track","bullets":["Cash $52.3M at March 31, up from $9.4M Dec 31, after $51M private placement from healthcare investors and JDRF T1D Fund.","Net loss $4.9M ($1.17/share) vs $4.5M ($2.16/share) in Q1 2023; revenue $1.0M from milestone.","R&D spend $2.6M, down from $3.9M YoY; G&A $4.0M, up from $3.5M.","First Phase 3 cadisegliatin trial in T1D expects first patient enrollment Q2 2024, top-line data Q1 2026.","Planning two international registrational trials for cadisegliatin in T1D starting 2026; T2D Phase 2 in Middle East on track H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000027","json":"https://secwatch.observer/filing/0001641489-24-000027.json","markdown":"https://secwatch.observer/filing/0001641489-24-000027.md","text":"https://secwatch.observer/filing/0001641489-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/0001641489-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/vtvt-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:09:45.243124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d786eea211e4d27c638d838a1b21e739035b0e4","claim":"vTv Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal period ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000027/0001641489-24-000027-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}